Heron Therapeutics, Inc.
HRTX
$1.36
-$0.05-3.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 149.69M | 148.52M | 144.29M | 137.74M | 136.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 149.69M | 148.52M | 144.29M | 137.74M | 136.36M |
| Cost of Revenue | 50.86M | 53.02M | 55.33M | 55.61M | 69.18M |
| Gross Profit | 98.84M | 95.50M | 88.95M | 82.13M | 67.18M |
| SG&A Expenses | 97.61M | 99.08M | 100.48M | 90.45M | 95.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 148.46M | 152.09M | 155.81M | 146.06M | 165.15M |
| Operating Income | 1.23M | -3.58M | -11.53M | -8.32M | -28.79M |
| Income Before Tax | -931.00K | -7.79M | -13.58M | -27.97M | -48.13M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.93 | -7.79 | -13.58 | -27.97 | -48.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -931.00K | -7.79M | -13.58M | -27.97M | -48.13M |
| EBIT | 1.23M | -3.58M | -11.53M | -8.32M | -28.79M |
| EBITDA | 3.56M | -1.22M | -9.04M | -5.70M | -26.02M |
| EPS Basic | -0.01 | -0.05 | -0.09 | -0.18 | -0.32 |
| Normalized Basic EPS | 0.00 | -0.02 | -0.05 | -0.04 | -0.13 |
| EPS Diluted | -0.02 | -0.06 | -0.09 | -0.18 | -0.32 |
| Normalized Diluted EPS | 0.00 | -0.03 | -0.05 | -0.04 | -0.13 |
| Average Basic Shares Outstanding | 613.49M | 611.78M | 609.49M | 609.53M | 601.69M |
| Average Diluted Shares Outstanding | 656.92M | 655.21M | 609.49M | 609.53M | 601.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |